Aterian, Inc. Form 8-K Summary
Business Context and Reporting Period
Aterian, Inc. filed a Form 8-K dated April 1, 2022, under Item 5.02 to report the appointment of a new director and related compensation arrangements. The filing does not report quarterly or annual financial results.
Key Financial and Corporate Metrics
- Financial results: The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
- Board appointment: Cynthia Williams was appointed as a Class II director effective April 1, 2022.
- Board committees: Ms. Williams will serve on the Audit Committee and the Nominating and Corporate Governance Committee.
- Term: Her initial term is expected to expire at the company’s 2024 annual stockholders’ meeting.
- Equity award: Ms. Williams received a restricted stock award covering 82,305 shares of common stock. The award vests over three years: one-third after one year, with the remainder vesting quarterly in equal installments thereafter, subject to continued service.
Material Changes, Outlook, and Risks
The material change disclosed is the addition of Ms. Williams to Aterian’s board and its Audit and Nominating and Corporate Governance Committees. The company also entered into an indemnification agreement with her in substantially the same form as its standard director agreements.
The filing states that Ms. Williams has no family relationship with any Aterian director or executive officer, was not appointed pursuant to an arrangement with another person, and has no reportable related-party transaction under Item 404(a) of Regulation S-K.
The filing provides no management guidance, financial outlook, contingency disclosures, or discussion of operating risks. It includes a press release announcing the appointment as Exhibit 99.1.
Important Facts to Verify
- Confirm the 82,305-share restricted stock award and its three-year vesting schedule.
- Review the company’s equity compensation disclosures for the accounting impact of the director award.
- Confirm Ms. Williams’s committee assignments and expected term through the 2024 annual meeting.
- Review Exhibit 99.1 for any additional statements regarding the appointment.
- Consult other Aterian filings for financial results, liquidity, debt, guidance, and broader business risks, which are not covered in this Form 8-K.